H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $90 from $80 and keeps a Buy rating on the shares. The company reported positive results from its Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1, the analyst tells investors in a research note. The firm upped its probability of approval to 90% from 80% and believes encaleret could be submitted for approval to the FDA during the first half of 2026 with market entry either in late 2026 or early 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio announces Phase 3 study of encaleret met primary endpoint
- Optimistic Buy Rating for BridgeBio Pharma: Promising Phase 3 Trial Results and Future Developments
- BridgeBio price target raised to $76 from $58 at BofA
- BridgeBio price target raised to $80 from $70 at H.C. Wainwright
- Positive Outlook for BridgeBio Pharma: Buy Rating Affirmed on Strong Phase 3 Trial Results and Strategic Market Positioning